{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:53:09Z","timestamp":1782327189343,"version":"3.54.5"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,11,30]],"date-time":"2015-11-30T00:00:00Z","timestamp":1448841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the impact and results of treatment of <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> in the general population, we conducted a population\u2010based, nationwide study on 3585 <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> patients diagnosed between 1989 and 2012 in the Netherlands.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patient demographics were obtained from the Netherlands Cancer Registry. Information on age, gender, year of diagnosis, first treatment, and date of death were recorded. Overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) was adjusted for death rates in the normal population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Incidence in males decreased slightly from 1.2 per 100.000 person years (<jats:styled-content style=\"fixed-case\">PY<\/jats:styled-content>) in 1989\u20132000 to 0.9 in 2001\u20132012. For females, incidence remained stable with 0.7 per 100.000 <jats:styled-content style=\"fixed-case\">PY<\/jats:styled-content> in both periods. Incidence was age dependent and highest in males in the last decades of life. Treatment before 2000 mainly consisted of chemotherapy, while after 2007 <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content> use was 88%. Five\u2010year relative survival was only 36% before the introduction of <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>s but significantly increased to 79% after the introduction of <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study gives insight into <jats:styled-content style=\"fixed-case\">CML<\/jats:styled-content> incidence, treatment, and survival in routine care in the Netherlands. Although <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> improved since the introduction of <jats:styled-content style=\"fixed-case\">TKI<\/jats:styled-content>s, there is still room for further improvement.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12695","type":"journal-article","created":{"date-parts":[[2015,10,31]],"date-time":"2015-10-31T16:13:02Z","timestamp":1446307982000},"page":"145-154","source":"Crossref","is-referenced-by-count":37,"title":["Chronic myeloid leukemia in the Netherlands: a population\u2010based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012"],"prefix":"10.1111","volume":"97","author":[{"given":"Noortje","family":"Thielen","sequence":"first","affiliation":[{"name":"Department of Hematology VU University Medical Center Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Visser","sequence":"additional","affiliation":[{"name":"Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht the\u00a0Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Ossenkoppele","sequence":"additional","affiliation":[{"name":"Department of Hematology VU University Medical Center Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Hematology VU University Medical Center Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International Randomized Study of Interferon vs STI571 (IRIS) 8\u2010year follow\u2010up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib","volume":"114","author":"Deininger M","year":"2009","journal-title":"Blood"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4920"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-376087"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410688"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.36"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13108"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.129221"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004095"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23330"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0807-x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-232595"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"e_1_2_6_18_1","unstructured":"Netherlands Comprehensive Cancer Organisation (IKNL).www.iknl.nl."},{"key":"e_1_2_6_19_1","volume-title":"International Classification of Diseases for Oncology","year":"1976"},{"key":"e_1_2_6_20_1","volume-title":"International Classification of Diseases for Oncology","author":"Percy C","year":"1990"},{"key":"e_1_2_6_21_1","volume-title":"International Classification of Diseases for Oncology","author":"Fritz A","year":"2000"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200421110-00004"},{"key":"e_1_2_6_23_1","first-page":"1400","article-title":"The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England","volume":"91","author":"Phekoo KJ","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-252"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2011.01637.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5851.89792"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7146"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-359"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.745525"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.04.003"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-495598"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28106"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.73"},{"key":"e_1_2_6_34_1","unstructured":"Surveillance Epidemiology and END results Program.www.seer.cancer.gov."},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_6_37_1","unstructured":"Integraal Kankercentrum Nederland.www.cijfersoverkanker.nl"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702420"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0393"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-617993"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12695","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T20:31:46Z","timestamp":1696365106000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,30]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/ejh.12695"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12695","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,30]]}}}